Mermer, Sinan
Loading...
Profile URL
Name Variants
Job Title
Email Address
sinan.mermer@ieu.edu.tr
Main Affiliation
09.02. Internal Sciences
Status
Current Staff
Website
ORCID ID
Scopus Author ID
Turkish CoHE Profile ID
Google Scholar ID
WoS Researcher ID
Sustainable Development Goals
1NO POVERTY
0
Research Products
2ZERO HUNGER
0
Research Products
3GOOD HEALTH AND WELL-BEING
1
Research Products
4QUALITY EDUCATION
0
Research Products
5GENDER EQUALITY
0
Research Products
6CLEAN WATER AND SANITATION
0
Research Products
7AFFORDABLE AND CLEAN ENERGY
0
Research Products
8DECENT WORK AND ECONOMIC GROWTH
0
Research Products
9INDUSTRY, INNOVATION AND INFRASTRUCTURE
0
Research Products
10REDUCED INEQUALITIES
0
Research Products
11SUSTAINABLE CITIES AND COMMUNITIES
0
Research Products
12RESPONSIBLE CONSUMPTION AND PRODUCTION
0
Research Products
13CLIMATE ACTION
0
Research Products
14LIFE BELOW WATER
0
Research Products
15LIFE ON LAND
1
Research Products
16PEACE, JUSTICE AND STRONG INSTITUTIONS
0
Research Products
17PARTNERSHIPS FOR THE GOALS
0
Research Products
Documents
14
Citations
99
h-index
7
Documents
0
Citations
0
Scholarly Output
3
Articles
3
Views / Downloads
7/0
Supervised MSc Theses
0
Supervised PhD Theses
0
WoS Citation Count
0
Scopus Citation Count
0
Patents
0
Projects
0
WoS Citations per Publication
0.00
Scopus Citations per Publication
0.00
Open Access Source
3
Supervised Theses
0
| Journal | Count |
|---|---|
| BMC Infectious Diseases | 1 |
| BMC Microbiology | 1 |
Current Page: 1 / 1
Scopus Quartile Distribution
Competency Cloud
3 results
Scholarly Output Search Results
Now showing 1 - 3 of 3
Article Cefixime-Clavulanic Acid in ESBL-Producing E. coli Lower Urinary Tract Infections: A 13-Patient Case Series(BMC, 2025-09-29) Mermer, Sinan; Akyol, Deniz; Ozkara, Mehmet Bugra; Aydemir, Sabire Sohret; Sipahi, Oguz ResatBackgroundUrinary tract infections (UTIs) represent a substantial proportion of community-acquired infections. The increasing prevalence of Escherichia coli strains that produce extended spectrum beta-lactamases (ESBL) poses a significant obstacle to effective infection treatment. Although carbapenems remain highly effective against ESBL-producing isolates, their use in lower UTIs is limited by the need for intravenous or intramuscular administration, hospitalization, high cost, and the risk of collateral damage due to their broad-spectrum activity. Therefore, there is a growing need for effective oral alternatives.MethodsThis retrospective study evaluated the clinical and microbiological outcomes of 13 patients diagnosed with lower UTIs caused by ESBL-producing E. coli (ESBL-PE), treated with oral cefixime-clavulanic acid (400/125 mg every 12 hours for 14 days). Follow-up urine cultures were obtained on days 3-5 and/or at the end of treatment (days 11-14).ResultsOn days 3-5 of treatment, microbiological and clinical success rates were 53.8% (7/13) and 61.5% (8/13) respectively. At the end of the treatment, urine culture results could be evaluated in 10 cases, microbiological success was 80% (8/10). Clinical success was 84.6% (11/13). Re-infection and relapse rates on day 30 post-treatment were 7.7% (1/13) and 30.8% (4/13), respectively.ConclusionsCefixime-clavulanic acid may be considered an alternative to older antibiotics such as fosfomycin and nitrofurantoin in the treatment of uncomplicated urinary tract infections, and may also contribute to the prevention of carbapenem resistance development. However, these findings should be interpreted with caution due to important limitations, including the small sample size, retrospective design, absence of standardized minimum inhibitor concentration (MIC) testing, and lack of a control group. Larger prospective studies are needed to confirm these results.Article Prevalence and Resistance Profiles of Acinetobacter Baumannii in the Intensive Care Unit: A Retrospective Analysis Between 2023 and 2025(Bilimsel Tip Yayinevi, 2026-03-10) Mermer, Sinan; Caglayan, ErtugrulIntroduction: This study investigated the prevalence and antimicrobial resistance profiles of Acinetobacter baumannii strains isolated from a tertiary intensive care unit between 2023 and 2025. Materials and Methods: Between January 2023 and August 2025, A. baumannii strains isolated from various clinical specimens in a tertiary intensive care unit were retrospectively analyzed. Identification and antibiotic susceptibility testing of the isolates were performed using the BD Phoenix 100 M50 (Becton Dickinson Company, USA) automated system, and the results were interpreted according to the standards of the European Committee on Antimicrobial Susceptibility Testing. Only one isolate per patient was included in the study. Results: A total of 566 A. baumannii isolates were evaluated. The annual isolation rates were 13.7% in 2023, 12.5% in 2024, and 17.5% in 2025, with an overall three-year average of 14.7%. Of these isolates, 77.4% were obtained from tracheal aspirates and 16.6% from blood cultures. The lowest resistance rates were observed for colistin (10.2%) and tigecycline (11.4%), while resistance rates exceeded 90% for carbapenems, aminoglycosides, and fluoroquinolones. Trend analysis revealed a significant decrease in tigecycline resistance (p< 0.001), whereas significant increasing trends were observed for cefoperazone-sulbactam, gentamicin, fluoroquinolones, cephalosporins, and carbapenems. Conclusion: A. baumannii remains a clinically significant pathogen in intensive care units and exhibits high resistance rates, particularly against broad-spectrum antibiotics. In our study, colistin and tigecycline were observed to retain relative activity. Regular surveillance of resistance patterns and the revision of empirical treatment protocols in light of these data may contribute to reducing mortality and morbidity rates.Article Prevalence, Clinical Characteristics, and Antibiotic Resistance of Carbapenem-Resistant Klebsiella Pneumoniae in a Tertiary Hospital in Türkiye (2023–2025)(BioMed Central Ltd, 2026-01-24) Mermer, S.; Çağlayan, E.Background: Carbapenem-resistant Klebsiella pneumoniae (CRKP) represents a growing public health threat due to limited treatment options, high morbidity and mortality rates. This study aimed to investigate the prevalence, clinical characteristics, and antibiotic resistance profiles of CRKP isolates identified in a tertiary hospital in Türkiye between 2023 and 2025. Methods: A retrospective observational study was conducted using microbiological and clinical data collected from patients diagnosed with CRKP infections between January 2023 and April 2025. A total of 1588 CRKP isolates were retrospectively analyzed and compared with patient clinical data. Bacterial identification and antimicrobial susceptibility testing were performed using the BD Phoenix 100 M50 automated system (Becton Dickinson Company, USA), and results were interpreted in accordance with the European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines. Results: Among 2376 K. pneumoniae isolates, the overall CRKP prevalence was 66.8%. The annual carbapenem resistance rates were 64.9% in 2023, 69.4% in 2024, and 61.0% in 2025, respectively. Resistance rates among CRKP isolates were as follows: tigecycline 14.7%, colistin 23.0%, fosfomycin 47.6%, ceftazidime-avibactam 50.9%, and amikacin 66.8%. The prevalence of CRKP was significantly higher among inpatients (83.8%) compared to outpatients (26.8%). Of the CRKP-positive samples, 62.5% were collected from patients in intensive care units (ICUs), 12.2% from hematology, and 5.1% from oncology departments. Tracheal aspirates accounted for 43.5% of isolates, followed by urine samples at 25.8%. Conclusions: The study revealed a notably high prevalence of CRKP with substantial resistance to most commonly used antibiotics. Among the tested antibiotics, tigecycline showed the lowest resistance rate, consistent with its limited usage profile. These findings underscore the urgent need for strengthened infection control measures and may guide more effective empirical treatment strategies for CRKP infections in the region. © The Author(s) 2026.
